The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following multiple-dose.
This is a multi-dose escalation study of HB0034 to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HB0034.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
30
HB0034 and Placebo
New zealand Clinical Research
Auckland, New Zealand
Percentage of subjects with drug related adverse events (AEs)
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational drug
Time frame: up to 2000 hours
Cmax
The maximum measured concentration of the analysis in plasma
Time frame: up to 2000 hours
AUC0-infinity
The area under the concentration-time curve of the analysis in plasma over the time interval from 0 extrapolated to infinity
Time frame: up to 2000 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.